Last update 01 Nov 2024

IL-15Rα x CD16a x BCMA

Basic Info

Related Targets
IL-15RαCD16aBCMA

Related

1
Drugs associated with IL-15Rα x CD16a x BCMA
FT-576
Target
BCMA x CD16a x IL-15Rα
Mechanism
BCMA inhibitors [+2]
Active Org.
Fate Therapeutics, Inc.Fate Therapeutics, Inc.
Originator Org.
Fate Therapeutics, Inc.Fate Therapeutics, Inc.
Active Indication
Plasma cell myeloma refractory [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with IL-15Rα x CD16a x BCMA
NCT05182073 / Active, not recruitingPhase 1
A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma
100 Clinical Results associated with IL-15Rα x CD16a x BCMA
Login to view more data
100 Translational Medicine associated with IL-15Rα x CD16a x BCMA
Login to view more data
0 Patents (Medical) associated with IL-15Rα x CD16a x BCMA
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free